InBrain Pharma, a CNS disorders focused biotech, founded in 2018, exploiting through an exclusive worldwide patent license signed with the Northern France TTO, a groundbreaking therapeutic approach of advanced Parkinson’s Disease based on the research work of Pr David DEVOS and Pr Caroline MOREAU developed within their academic research Team from the Université́ de Lille, Lille Neuroscience & cognition UMR-S 1172 INSERM and the Lille University Hospital. To date, the company has raised €4.4 million in dilutive and non-dilutive financing, these funds having enabled to carry out a first phase I/IIb DIVE-I clinical trial on 12 patients, for which results have just been obtained.
Company Details
- Employees
- 5
- Founded
- -
- Address
- 70, Rue Du Docteur Yersin, Loos,hauts-De-France 59120,france
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- inbrainpharma.com
- HQ
- Loos, Hauts-de-France
Inbrain Pharma Questions
Inbrain Pharma's website is inbrainpharma.com
Inbrain Pharma's LinkedIn profile is https://fr.linkedin.com/company/in-brain-pharma
Inbrain Pharma has
5 employees.
View email and phone details for 5
employees at Inbrain Pharma.
Inbrain Pharma's industry is
Biotechnology Research
Inbrain Pharma's top competitors are
Huntx Pharma,
Neuvivo,
Chipiron,
Okomera,
Nūmi®,
Avalun,
Inhibikase Therapeutics, Inc.,
Orakl Oncology,
Brenus Pharma,
Invenis Biotherapies.
Inbrain Pharma's categories are Biotechnology Research
Inbrain Pharma's founding year is 2018
